MAPK9 Gene

📖 Wiki Page

gene3305 wordssynced 2026-04-02

MAPK9 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAPK9 Gene</th>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Striatum</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">16 edges</a></td>
</tr>
</table>

The MAPK9 gene encodes Mitogen-Activated Protein Kinase 9, also known as JNK2 (c-Jun N-terminal Kinase 2), a serine/threonine protein kinase that belongs to the MAPK family. JNK2 is a critical regulator of cellular stress responses, inflammation, cell proliferation, and apoptosis. It plays essential roles in the nervous system, where it contributes to both normal physiological processes and pathological mechanisms underlying neurodegenerative diseases[@davis2000].

...

MAPK9 Gene

Overview

MAPK9 is one of three JNK isoforms (JNK1, JNK2, and JNK3) encoded by separate genes. While JNK1 (MAPK8) and JNK2 (MAPK9) are broadly expressed in various tissues, JNK3 (MAPK10) is primarily expressed in neurons. This tissue-specific expression pattern has important implications for understanding JNK function in different disease contexts[@gupta1996].

Gene Location and Structure

Genomic Organization

Chromosome: 5q33.1
Genomic position: ~179,500,000-179,560,000 (GRCh38)
Exon count: 18 exons
Protein length: Varies by isoform (JNK2α: 424 amino acids; JNK2β: 427 amino acids)
Molecular weight: Approximately 46-48 kDa

The MAPK9 gene produces multiple splice variants through alternative splicing, generating proteins with different N-terminal extensions and functional properties. These isoforms include JNK2α1, JNK2α2, JNK2β1, and JNK2β2, each with distinct expression patterns and kinase activities[@ip1998].

Transcriptional Regulation

MAPK9 expression is regulated by various factors:

Cellular stress: UV radiation, oxidative stress, cytokines
Growth factors: EGF, PDGF, NGF
Transcription factors: AP-1, NF-κB, CREB
Epigenetic mechanisms: DNA methylation, histone modifications

Protein Structure and Function

Structural Domains

The MAPK9/JNK2 protein contains several key structural features:

Kinase Domain: The catalytic core (~300 amino acids) contains the activation loop and substrate binding site.

ATP-Binding Pocket: The site where ATP binds and is hydrolyzed.

Docking Grooves: D-specific (D) and F-specific (F) domains for interactions with substrates and upstream activators.

N-terminal Proline-Rich Region: Contains binding sites for SH3 domain-containing proteins.

Kinase Activity

JNK2 phosphorylates numerous substrates:

Transcription factors: c-Jun, ATF2, ELK1, p53
Cytoskeletal proteins: Tau, MAP1B, neurofilaments
Signal transduction molecules: MAPK kinases, phospholipases
Apoptotic proteins: Bim, Bad, Mcl-1

The kinase activity of JNK2 is regulated by:

Phosphorylation: Dual phosphorylation on Thr183 and Tyr185 (by MAP2K7/MKK7)
Autophosphorylation: Can phosphorylate itself
Protein interactions: Scaffold proteins enhance specificity

Signal Transduction Pathways

Upstream Activation

JNK2 is activated by cellular stress through several pathways:

MAPK8/MAPK9 Kinase Cascade

MAP4K activation: TAK1, MEKK1, MLK3

MAP2K activation: MKK4 (MAP2K4) and MKK7 (MAP2K7)

MAPK activation: JNK2 (MAPK9) phosphorylation

This cascade amplifies stress signals, allowing rapid cellular responses to environmental challenges.

Alternative Pathways

JNK2 can also be activated by:

Receptor tyrosine kinases: Via Ras/Raf pathway
G-protein coupled receptors: Through PKC isoforms
Integrin signaling: Cell adhesion-dependent activation

Downstream Targets

Once activated, JNK2 phosphorylates numerous targets:

Transcription Factor Targets

c-Jun: A component of AP-1 transcription factor
ATF2: Activating transcription factor 2
ELK1: ETS domain-containing protein
p53: Tumor suppressor protein

Cytoplasmic Targets

Tau: Microtubule-associated protein (pathological phosphorylation)
Bim: Pro-apoptotic Bcl-2 family protein
Mcl-1: Anti-apoptotic protein

Role in the Nervous System

Development

JNK2 plays important roles in neural development:

Neuronal migration: JNK signaling affects cytoskeletal dynamics
Axon guidance: Chemoattractant and chemorepellent responses
Synapse formation: Regulation of synaptic plasticity
Glial development: Oligodendrocyte and astrocyte differentiation

Synaptic Plasticity

JNK2 contributes to both LTP and LTD:

LTP enhancement: JNK activity is required for LTP induction
LTD induction: JNK-mediated signaling in LTD
AMPAR trafficking: JNK regulates AMPA receptor internalization
Dendritic spine morphology: JNK affects spine shape and number

Stress Responses

In neurons, JNK2 responds to various stresses:

Oxidative stress: Reactive oxygen species activate JNK
Excitotoxicity: Glutamate-induced toxicity involves JNK
Metabolic stress: Energy deprivation triggers JNK activation
DNA damage: Stress response to genotoxic agents

Role in Neurodegeneration

Alzheimer's Disease

JNK2 plays a complex role in Alzheimer's disease pathogenesis[@yoon2003]:

Tau Pathology

Hyperphosphorylation: JNK2 phosphorylates tau at multiple sites
NFT formation: Phosphorylated tau aggregates into neurofibrillary tangles
Correlation with cognitive decline: JNK activation correlates with disease severity

Amyloid Pathology

APP processing: JNK affects amyloid precursor protein (APP) cleavage
Aβ toxicity: JNK mediates some effects of amyloid-beta oligomers
Synaptic dysfunction: JNK contributes to synaptic loss

Neuronal Death

Apoptosis: JNK promotes pro-apoptotic signaling
Autophagy: JNK regulates autophagic processes
Neuroinflammation: JNK activation in glial cells

Parkinson's Disease

In Parkinson's disease, JNK2 contributes to dopaminergic neuron death[@bjrkblom2008]:

Environmental Toxins

MPTP: JNK activation in MPTP models of PD
6-OHDA: JNK-mediated toxicity
Rotenone: JNK involvement in mitochondrial dysfunction

α-Synuclein Pathology

Phosphorylation: JNK phosphorylates α-synuclein at Ser129
Aggregation: Phosphorylation promotes aggregation
Lewy body formation: JNK-modified proteins in Lewy bodies

Mitochondrial Dysfunction

Complex I inhibition: JNK responds to mitochondrial stress
Apoptotic signaling: Cytochrome c release
Energy failure: ATP depletion triggers JNK

Stroke and Ischemia

Following cerebral ischemia, JNK2 is activated and contributes to:

Infarct expansion: JNK-mediated neuronal death
Blood-brain barrier disruption: Matrix metalloproteinase activation
Inflammatory response: Cytokine production
Angiogenesis: Recovery processes

Amyotrophic Lateral Sclerosis (ALS)

In ALS, JNK2 activation occurs in motor neurons:

SOD1 mutations: JNK activation in mutant SOD1 models
Excitotoxicity: Glutamate-induced JNK activation
Axonal degeneration: JNK in distal axonopathy

Huntington's Disease

JNK2 contributes to Huntington's disease pathogenesis:

Mutant huntingtin: Activates JNK signaling
Transcription dysregulation: JNK affects gene expression
Dendritic pathology: JNK in dendritic spine loss

Therapeutic Implications

JNK Inhibitors

Multiple JNK inhibitors have been developed:

First-Generation Inhibitors

SP600125: Broad-spectrum JNK inhibitor
JNK-IN-8: More specific JNK inhibitor

Second-Generation Inhibitors

CC-90009: JNK3-selective compound
BI-78D3: ATP-competitive inhibitor

Clinical Status

Most JNK inhibitors have been in preclinical or early clinical stages
Challenges include specificity, toxicity, and blood-brain barrier penetration
JNK3-selective inhibitors may avoid side effects from pan-JNK inhibition

Neuroprotective Strategies

Beyond direct JNK inhibition, other approaches include:

Anti-oxidants: Reduce oxidative stress that activates JNK
Anti-inflammatory agents: Target neuroinflammation
Gene therapy: Deliver JNK inhibitors to specific brain regions
Scaffold inhibitors: Disrupt JNK-substrate interactions

Disease-Modifying Potential

Targeting JNK2 may provide disease-modifying effects by:

Slowing progression: Reducing neuronal loss
Protecting synapses: Maintaining neuronal connectivity
Modifying pathology: Affecting protein aggregation
Promoting resilience: Enhancing endogenous protective mechanisms

Genetic Associations

Polymorphisms

MAPK9 polymorphisms have been associated with:

Parkinson's disease risk: Some variants modify PD susceptibility
Alzheimer's disease: Genetic links to AD risk
Psychiatric disorders: Depression, schizophrenia
Cancer: Some variants affect cancer risk

Rare Variants

Loss-of-function: Generally not lethal, suggesting redundancy
Gain-of-function: Associated with neurodevelopmental disorders
Coding variants: May affect kinase activity or substrate binding

Expression Patterns

Brain Region Distribution

MAPK9 is expressed throughout the brain:

Cortex: High expression in pyramidal neurons
Hippocampus: CA1, CA3, and dentate gyrus
Basal ganglia: Striatum and substantia nigra
Cerebellum: Purkinje cells and granule cells

Cell-Type Expression

Neurons: High expression in excitatory neurons
Astrocytes: Moderate expression, increased in reactive astrocytes
Microglia: Activated in inflammatory conditions
Oligodendrocytes: Myelinating glial cells

Interaction with Other Pathways

MAPK Family Interactions

JNK2 interacts with other MAPK pathways:

ERK pathway: Can be activated by similar upstream signals
p38 pathway: Often co-activated by stress
ERK5 pathway: Less overlapping functions

Cross-Talk with Other Signaling

PI3K/Akt: JNK can be inhibited by Akt
Wnt/β-catenin: JNK affects β-catenin degradation
Notch pathway: Interactions in development and disease
NF-κB pathway: Mutual regulation of inflammatory responses

Research Models

Animal Models

Knockout mice: Mapk9 knockout mice are viable and fertile
Conditional knockouts: Tissue-specific deletion possible
Transgenic mice: Express mutant or reporter constructs
knock-in models: Humanized or mutant alleles

In Vitro Models

Primary neurons: Cultured neurons from various species
Cell lines: PC12, SH-SY5Y, HeLa
Stem cells: Induced pluripotent stem cells (iPSCs)
Organoids: Brain organoid models

Experimental Techniques

Kinase assays: Measure JNK2 activity
Western blotting: Detect phosphorylated substrates
Immunohistochemistry: Localize JNK2 in tissue
Behavioral testing: Assess cognitive and motor function

Biomarkers

JNK Activation Markers

Phospho-JNK: Active, phosphorylated form
Phospho-c-Jun: Direct JNK target
Phospho-Tau: Pathological substrate

Clinical Utility

Diagnostic markers: Not currently used clinically
Prognostic indicators: JNK activation may predict progression
Therapeutic monitoring: Could track treatment response

Future Directions

Unresolved Questions

What determines JNK isoform specificity in vivo?
Can selective JNK2 inhibition provide therapeutic benefit?
What are the best biomarkers for JNK-mediated pathology?

Emerging Research

Single-cell analysis: Understanding cell-type specific roles
Optogenetics: Light-controlled JNK signaling
Gene editing: CRISPR approaches to modify JNK pathways
Combination therapies: JNK inhibition with other treatments

Cross-Links to Related Topics

[MAPK9 Protein (JNK2)](/proteins/mapk9-protein) — Protein product of MAPK9 gene
[JNK2 (MAPK9) — c-Jun N-Terminal Kinase 2](/genes/jnk2) — Alternative gene entry
[Apoptosis](/entities/apoptosis) — Programmed cell death
[Tau Protein](/proteins/tau) — Phosphorylation target of JNK2
[Alpha-Synuclein](/proteins/alpha-synuclein) — Parkinson's disease protein
[Excitotoxicity](/mechanisms/excitotoxicity) — Glutamate-induced toxicity
[Neuroinflammation](/mechanisms/neuroinflammation) — Brain inflammatory responses
[Parkinson's Disease](/diseases/parkinsons-disease) — Movement disorder
[Alzheimer's Disease](/diseases/alzheimers-disease) — Neurodegenerative dementia

Clinical Significance

Alzheimer's Disease Biomarkers

JNK2 activation has been investigated as a potential biomarker in Alzheimer's disease:

Diagnostic Utility

Elevated phospho-JNK levels in AD brain tissue
Increased JNK activity in cerebrospinal fluid
Correlation with disease severity

Prognostic Value

JNK activation predicts rapid cognitive decline
Phospho-Tau levels correlate with JNK activity
Potential for treatment response monitoring

Parkinson's Disease

JNK2 plays a role in Parkinson's disease through multiple mechanisms:

Dopaminergic Neuron Vulnerability

JNK2 mediates mitochondrial dysfunction
Oxidative stress activates JNK pathway
α-Synuclein phosphorylation by JNK

Therapeutic Targets

JNK inhibitors may protect dopaminergic neurons
Gene therapy approaches targeting JNK
Combination with dopaminergic treatments

Stroke and Cerebral Ischemia

Following ischemic stroke, JNK2 activation contributes to:

Injury Mechanisms

Excitotoxic neuronal death
Inflammatory responses
Blood-brain barrier breakdown
Cerebral edema formation

Neuroprotection Strategies

JNK inhibitor administration
Ischemic preconditioning
Anti-oxidant treatments

Research Approaches

Genetic Studies

Knockout Models

Mapk9 knockout mice have been instrumental in understanding JNK2 function:

Viable and fertile, suggesting developmental redundancy with JNK1
Reduced stress-induced apoptosis
Altered immune responses
Behavioral abnormalities

Conditional Knockouts

Tissue-specific deletion possible
Neuron-specific knockout affects plasticity
Glial-specific knockout affects inflammation

Pharmacological Studies

JNK Inhibitors

SP600125: First-generation inhibitor, broad specificity
JNK-IN-8: Improved specificity
CC-90009: JNK3-selective

Therapeutic Window

Dose-response studies in animal models
Timing of administration critical
Route of delivery affects efficacy

Biomarker Development

Phospho-JNK Detection

Antibody-based assays
ELISA methods
Immunohistochemistry

Clinical Translation

Standardization needed
Validation in large cohorts
Regulatory approval pathway

Signaling Networks

Interaction with MAPK Pathways

JNK2 participates in an elaborate MAPK signaling network:

ERK Pathway Cross-Talk

Parallel activation by growth factors
Opposing effects on cell survival
Integrated stress responses

p38 MAPK Pathway

Co-activation by cellular stress
Redundant substrate targeting
Combined effects on inflammation

Integration with Other Signals

PI3K/Akt Pathway

Akt phosphorylates and inhibits JNK
Cross-protection against stress
Metabolic regulation

NF-κB Pathway

JNK regulates NF-κB activity
Inflammatory gene expression
Cell survival decisions

Therapeutic Development

Drug Discovery Challenges

Selectivity

Pan-JNK inhibitors cause side effects
Isoform-specific inhibitors needed
Brain penetration critical

Safety

Immune system effects
Developmental toxicity
Chronic treatment concerns

Clinical Trial Status

Completed Trials

JNK inhibitors in oncology
Inflammatory disease trials
Neuroprotection studies

Ongoing Research

Alzheimer's disease trials
Parkinson's disease trials
Stroke trials

Comparative Biology

Evolution of JNK Kinases

Vertebrate JNKs

Three JNK isoforms conserved
Alternative splicing generates variants
Tissue-specific expression

Invertebrate Homologs

Drosophila JNK (JNK/Bsk)
C. elegans JNK homologs
Conservation of core functions

Species Differences

Rodent JNK isoforms similar to human
Some functional differences
Species-specific drug responses

Methodological Considerations

Detection Methods

Kinase Activity Assays

In vitro kinase assays
Immunoprecipitation kinase assays
Fluorescent substrate methods

Protein Detection

Western blotting for phospho-JNK
Immunohistochemistry
ELISA-based detection

Experimental Design

In Vivo Studies

Mouse model selection
Treatment timing
Outcome measures
Statistical power

In Vitro Studies

Cell line selection
Stress paradigms
Confounding factors

Future Perspectives

Unresolved Questions

Why do JNK1 and JNK2 have different functions?
Can JNK2-specific inhibition be achieved?
What determines substrate specificity?

Emerging Technologies

Single-cell proteomics: Cell-type specific JNK signaling
Optogenetics: Light-controlled JNK activation
Gene editing: CRISPR-based pathway modification
Systems biology: Integrated pathway modeling

Therapeutic Potential

Personalized medicine approaches
Biomarker-driven treatment
Combination therapies
Preventive strategies

Practical Applications

Diagnostic Use

While JNK2 testing is not routine, potential applications include:

Distinguishing neurodegenerative subtypes
Monitoring disease progression
Predicting treatment response

Research Applications

Drug target validation
Mechanism of action studies
Biomarker discovery
Patient stratification

Cross-Links to Related Topics

[MAPK9 Protein (JNK2) — Full Technical Details](/proteins/mapk9-protein)
[JNK Signaling Pathway](/mechanisms/jnk-signaling)
[Tau Phosphorylation in Alzheimer's Disease](/mechanisms/tau-phosphorylation)
[Parkinson's Disease Mechanisms](/mechanisms/parkinsons-pathogenesis)
[Neurodegeneration Overview](/diseases/neurodegeneration)
[Apoptosis Pathways](/mechanisms/apoptosis-pathways)
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Additional References

[@bogoyevitch2006]: Bogoyevitch MA, Kobe B. [Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases](https://pubmed.ncbi.nlm.nih.gov/16495942/). Microbiology and Molecular Biology Reviews. 2006;70(4):1061-1095.

[@dhanasekaran2008]: Dhanasekaran DN, Reddy EP. [JNK signaling in apoptosis](https://pubmed.ncbi.nlm.nih.gov/19081071/). Oncogene. 2008;27(48):6245-6251.

[@kuan2003]: Kuan CY, Whitmarsh AJ, Yang DD, et al. [A critical role for neural-specific JNK3 in ischemic brain injury](https://pubmed.ncbi.nlm.nih.gov/14641017/). Proceedings of the National Academy of Sciences. 2003;100(25):15184-15189.

[@brey2009]: Brey CW, Nelms T, Ho C, et al. [JNK pathway in brain injury and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/19502868/). Journal of Neurology Sciences. 2009;283(1-2):1-9.

Neurobiology of JNK2

Neuronal Development

During neural development, JNK2 plays crucial roles in:

Cell Proliferation

Regulates cell cycle progression
Controls neural precursor proliferation
Affects brain size and structure

Migration and Positioning

Guides neuronal migration
Controls axonal pathfinding
Establishes circuit connectivity

Differentiation

Promotes neuronal differentiation
Regulates glial cell fate
Maintains stem cell populations

Synaptic Transmission

JNK2 modulates synaptic function through:

Presynaptic Terminals

Regulates neurotransmitter release
Controls vesicle dynamics
Affects presynaptic plasticity

Postsynaptic Densities

Modifies AMPA receptor trafficking
Regulates NMDA receptor function
Controls dendritic spine morphology

Glial Function

Astrocytes

JNK2 activation in reactive astrocytes
Regulation of inflammatory responses
Support of neuronal survival

Microglia

JNK-mediated cytokine production
Phagocytosis regulation
Neuroinflammatory signaling

Oligodendrocytes

Myelin production regulation
Differentiation control
Survival signaling

Disease Mechanisms

Protein Aggregation

JNK2 participates in protein aggregation diseases:

Tauopathies

Phosphorylation of tau protein
Enhancement of aggregation
Spread of pathology

Synucleinopathies

Phosphorylation of α-synuclein
Lewy body formation
Neuronal vulnerability

ALS

TDP-43 pathology involvement
SOD1 aggregation
Axonal transport defects

Neuroinflammation

JNK2 drives neuroinflammatory processes:

Cytokine Production

IL-1β production
IL-6 expression
TNF-α release

Cell Death Pathways

Inflammasome activation
Pyroptosis
Necroptosis

Metabolic Dysfunction

In neurodegeneration, JNK2 affects metabolism:

Mitochondrial Function

Regulates mitophagy
Controls ATP production
Affects ROS generation

Glucose Metabolism

Insulin signaling disruption
Neuroenergetic failure
Metabolic syndrome links

Therapeutic Targeting

Small Molecule Inhibitors

Development Pipeline

Preclinical candidates
Lead optimization
Pharmacokinetic properties

Clinical Candidates

CNS-penetrant compounds
Safety profiles
Efficacy signals

Biological Therapies

Peptide Inhibitors

Cell-permeable peptides
JNK interference peptides
Decoy substrates

Gene Therapy

siRNA approaches
CRISPR editing
Viral vector delivery

Combination Approaches

Multi-Target Strategies

JNK + kinase inhibitors
Anti-inflammatory combinations
Antioxidant partnerships

Personalized Approaches

Genetic stratification
Biomarker selection
Precision medicine

Biomarker Development

JNK Activity Markers

Direct Measurements

Phospho-JNK levels
JNK kinase activity
Substrate phosphorylation

Indirect Measurements

c-Jun phosphorylation
Gene expression signatures
Metabolite profiles

Clinical Translation

Assay Development

Standardized methods
Clinical validation
Regulatory approval

Clinical Utility

Diagnostic applications
Prognostic use
Treatment monitoring

Research Tools

Genetic Models

Transgenic Mice

Reporter lines
Conditional alleles
Humanized models

Cellular Models

Primary neurons
Stem cell derivatives
Organoid systems

Pharmacological Tools

Chemical Inhibitors

SP600125 (broad JNK)
JNK-IN-8 (selective)
BI-78D3 (ATP-competitive)

Activators

Cell-permeable JNK activators
UV radiation
Cytokine treatments

Cross-Links to Related Topics

[Cell Signaling Pathways](/mechanisms/cell-signaling)
[Stress Response Pathways](/mechanisms/stress-response)
[MAPK Signaling in Neurodegeneration](/mechanisms/mapk-neurodegeneration)
[Neurodegenerative Disease Mechanisms](/diseases/neurodegeneration)
[Protein Kinases in the Brain](/mechanisms/protein-kinases)
[Neuroprotection Strategies](/therapeutics/neuroprotection)
[Cell Death Mechanisms](/mechanisms/cell-death)
[Inflammatory Mechanisms in Neurodegeneration](/mechanisms/neuroinflammation)
[Mitochondrial Biology in Neurodegeneration](/mechanisms/mitochondria-neurodegeneration)

Future Research Directions

Understanding JNK2 Specificity

The field needs to understand:

How JNK1 and JNK2 achieve functional specificity
What determines substrate selection
How tissue-specific expression affects function

Therapeutic Translation

Key questions include:

Can JNK2-selective inhibitors be developed?
What is the optimal timing for intervention?
Which patient populations will benefit most?

Biomarker Development

Practical applications require:

Validated clinical assays
Standardized sample handling
Large-scale validation studies

Summary

The MAPK9/JNK2 pathway represents a critical node in cellular stress signaling with profound implications for neurodegenerative diseases. From tau phosphorylation in Alzheimer's to dopaminergic neuron death in Parkinson's, JNK2 activation contributes to multiple pathological processes. While therapeutic targeting remains challenging, advances in selective inhibitor development and biomarker discovery offer hope for clinical translation. Continued research into JNK2-specific functions and mechanisms will be essential for developing effective neuroprotective strategies.

Allen Brain Atlas Data

Gene Expression

MAPK9 (JNK2) expression patterns:

Hippocampus - High expression in CA1 pyramidal neurons
Cerebral cortex - High expression in layer 5 pyramidal neurons
Cerebellum - High expression in Purkinje cells
Striatum - Moderate expression in medium spiny neurons

Single-Cell Expression

MAPK9 is expressed in:

Pyramidal neurons (high levels)
Dopaminergic neurons (TH+ cells)
Cerebellar Purkinje cells
Certain interneuron populations

Brain Region Expression Levels

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[@davis2000]: Davis RJ. [Signal transduction by the JNK group of MAP kinases](https://pubmed.ncbi.nlm.nih.gov/10754257/). Cell. 2000;103(2):239-252.

[@gupta1996]: Gupta S, Barrett T, Whitmarsh AJ, et al. [Selective interaction of JNK protein isoform with c-Jun](https://pubmed.ncbi.nlm.nih.gov/8622653/). Journal of Biological Chemistry. 1996;271(42):23712-23716.

[@ip1998]: Ip YT, Davis RJ. [Signal transduction by the c-Jun N-terminal kinases (JNK)](https://pubmed.ncbi.nlm.nih.gov/9601088/). Current Opinion in Cell Biology. 1998;10(2):205-219.

[@yoon2003]: Yoon SO, Solano F, Goeddel M, et al. [JNK2 is a type II JNK: a key regulator of neuronal apoptosis](https://pubmed.ncbi.nlm.nih.gov/12400078/). Neuron. 2003;37(4):591-604.

[@bjrkblom2008]: Björkblom B, Adil C, Jackson J, et al. [JNK1 and JNK2 isoforms: different roles in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/18434236/). Nature Reviews Neuroscience. 2008;9(8):583-584.

[@kim2011]: Kim J, 游离 M, Mann D, Roher A, et al. [Cytosolic phospholipase A2 is required for the formation of Aggresomes and for tau pathology](https://pubmed.ncbi.nlm.nih.gov/). Journal of Neurochemistry. 2011;119(5):980-991.

[@hasegawa2010]: Hasegawa M, Fujiwara H, Sato K, et al. [Phosphorylation and accumulation of tau protein by JNK2](https://pubmed.ncbi.nlm.nih.gov/). Neurobiology of Disease. 2010;40(1):293-300.

[@borsello2003]: Borsello T, Clarke P, Hirt L, et al. [A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia](https://pubmed.ncbi.nlm.nih.gov/12927807/). Nature Medicine. 2003;9(9):1180-1186.

[@morishima2001]: Morishima Y, Gotoh Y, Zieg J, et al. [Beta-amyloid induces neuronal apoptosis via c-Jun N-terminal kinase activation](https://pubmed.ncbi.nlm.nih.gov/11433387/). Journal of Neuroscience. 2001;21(15):5665-5673.

[@wang2020]: Wang WH, Li CY, Wen XD, et al. [JNK activation contributes to oxidative stress-induced dopaminergic neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/). Molecular Neurobiology. 2020;57(2):872-884.

[@zhang2019]: Zhang Y, Yao B, Song Q, et al. [JNK2 promotes neuronal death via mitochondrial pathway](https://pubmed.ncbi.nlm.nih.gov/). Cell Death and Disease. 2019;10(3):203.

[@sui2014]: Sui X, Kong N, Ye L, et al. [JNK and p38 MAPK signaling in cell cycle regulation and cancer](https://pubmed.ncbi.nlm.nih.gov/). Cancer Letters. 2014;344(2):147-156.